EU ITN granted to MANIC
The EU Marie Curie Actions has awarded about EUR 4 million to MANIC (Materials for Neuromorphic Circuits), an Innovative Training Network, to be coordinated by Prof. Beatriz Noheda of the Zernike Institute for Advanced Materials (ZIAM) and co-coordinated by Dr. Jean Fompeyrine (IBM Research-Zurich). Prof. Jos Roerdink and Prof. Lambert Schomaker (Bernoulli Institute for Mathematics, Computer Science and Artificial Intelligence) also participate in this European multidisciplinary consortium.

The three professors are members of the CogniGron center, where the ideas behind MANIC originate from. The MANIC network will prepare fifteen young and talented scientists for the development of materials that can function as networks of neurons and synapses by integrating conductivity, plasticity and self-organization. These materials will become the key elements in a new generation of electronic devices that will be able to adapt to software and enable efficient learning.
In MANIC, the students will be trained in a highly multidisciplinary and international environment formed by twelve research groups and eleven partners from the private sector, based in Switzerland, France, Spain, Germany, United Kingdom, Belgium and the Netherlands.
Last modified: | 06 December 2019 09.07 a.m. |
More news
-
17 July 2025
Veni-grants for eleven UG researchers
The Dutch Research Council (NWO) has awarded a Veni grant of up to €320,000 each to eleven researchers of the University of Groningen and the UMCG: Quentin Changeat, Wen Wu, Femke Cnossen, Stacey Copeland, Bart Danon, Gesa Kübek, Hannah Laurens, Adi...
-
14 July 2025
ERC Proof of Concept grant for Kottapalli and Covi
Professors Ajay Kottapalli and Erika Covi have received Proof of Concept grants from the European Research Council (ERC).
-
10 July 2025
Dutch Research Agenda funding for nanomedicine research
Prof Dr Anna Salvati, Dr Christoffer Åberg and Prof Dr Siewert-Jan Marrink have been granted a National Science Agenda (NWA) funding to further develop life-saving drugs based on nanotechnology with the NanoMedNL consortium.